Daiichi Sankyo Korea and AstraZeneca Korea received approval for two additional Enhertu indications: 1L HER2-positive...

HLX43 received PMDA acknowledgment to initiate a global Phase 2/3 trial in squamous non-small cell...

InnoCare Pharma’s independently developed CDH17-targeted ADC innovative drug ICP B208 has been approved for clinical...

ArriVent announces IND clearance for novel tetravalent MUC16/NaPi2b targeting ADC ARR-002 with initial focus in...

Bristol Myers Squibb licenses Antibody-Drug Conjugate technology from Lonza

Waiv enters collaboration with Daiichi Sankyo to deliver AI-derived biomarkers for ADC program